Dr. David Chiswell has extensive experience in the development of early-stage biotechnology companies with over 30 years in the industry. He joins the SENISCA Board as Chairman, having co-founded Cambridge Antibody Technology (CAT; 1990) and served as its CEO (1996 to 2002). He also served as CEO of Nabriva Therapeutics (2009 to 2012), and Kymab (2015 to 2018). Dr. Chiswell currently serves as Chairman of Epsilogen Ltd. and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund (LSE:MNTN).

Dr. Chiswell has served as the Chairman of the Board of various biotechs including Albireo, Arrow and Sosei. He was also formerly Chairman of the UK BioIndustry Association, with his major contributions to the industry being recognized with the awarding of an OBE by HM the Queen in 2006.